PRINCETON, N.J.--(BUSINESS WIRE)--
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical
company focused on advanced wound care announced today that Barry
Wolfenson, the Company's Executive Vice President for Global Marketing
and Business Development will present a corporate overview and update at
the Bank of America Merrill Lynch 2012 Health Care Conference taking
place from Monday, May 14 - Thursday, May 17, 2012 at the Encore at the
Wynn in Las Vegas, Nevada. The Company's presentation will take place on
Wednesday, May 16, 2012 at 1:00 p.m. local time.
To listen and view the presentation investors may visit the investor
relations section of Derma Sciences' website at www.dermasciences.com.
An archived copy of the presentation will also be available on Derma
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments
of the wound care marketplace: pharmaceutical wound care products,
advanced wound care dressings and traditional dressings. Derma Sciences
has successfully completed the Phase 2 clinical trial in diabetic foot
ulcer healing with DSC127, an investigational pharmaceutical drug under
development for accelerated wound healing and scar reduction, and is
preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is
the leading brand of honey-based dressings for the management of wounds
and burns. The product has been shown to be effective in a variety of
indications, and was the focus of a positive large-scale, randomized
controlled trial involving 108 subjects with leg ulcers. Other novel
products introduced into the $14 billion global wound care market
include XTRASORB® for better management of wound exudate, BIOGUARD® for
infection prevention and TCC-EZ?, a gold-standard treatment for diabetic
For more information please visit www.dermasciences.com.